Exit Notice
You are about to leave ClinicalTrials.gov and go to: Click here for more information about this study: A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva (FOP) URL: http://clementiapharma.com/
Click on the link to continue or return to ClinicalTrials.gov Home